RU2139726C1 - Agent for treatment of patients with chronic prostatitis - Google Patents

Abstract

FIELD: medicine, urology, pharmacology. SUBSTANCE: invention proposes a new agent collalysin for treatment of patients with chronic prostatitis. An agent normalizes the hemostasis system. EFFECT: decreased treatment period, absence of adverse effects. 2 tbl, 2 ex

Description

 The invention relates to medicine, in particular to medicines, and can be used to treat patients with chronic prostatitis.

 Currently, the treatment of chronic prostatitis presents significant difficulties. However, in recent years there has been an increase in the number of patients with chronic prostatitis, a torpid course of the process and resistance to existing methods of therapy. The latter is largely due to changes in the hemostatic system, which, according to our studies, plays a significant role in the pathogenesis of prostatitis.

 Medicines for the treatment of chronic prostatitis are known: antibiotics, pyrogenal, biostimulants, hormones (3). However, they are often not effective. In addition, hormonal drugs can cause various side effects and complications: ulceration of the gastric mucosa with bleeding and perforation, acute psychoses, hypertension, osteoporosis, and manifestation of diabetes mellitus (4).

 The duration of treatment of chronic prostatitis with existing drugs is long and even using modern complex methods is at least 1.5 - 2 months or more (3).

 The use of the well-known domestic drug collizin (in the form of endourethral electrophoresis of 500 KU) is proposed as a means of treating chronic prostatitis. The drug is used as follows: in the position of the patient lying on his back by endourethral electrophoresis from the positive pole, 500 KE of collalysine are introduced in 3 ml of a 0.5% solution of novocaine, the duration of the procedure is 20 minutes at a current of 0.1 mA. On a course - 10 - 15 procedures.

 Collalizine is known as a therapeutic and prophylactic agent used for cicatricial changes in ophthalmic and cosmetic practice (1), as well as in the treatment of limited scleroderma (2). Nothing is known about the ability of collalizine to influence the state of hemostasis in chronic prostatitis.

 In clinical conditions, we first tested the drug collalizine in 24 patients with chronic prostatitis (of which post-trichomonas in 18, postgonorrheal in 1 and bacterial in 5) with a duration of the pathological process from 6 months to 3 years, which were disturbed by lower back pain, backache perineum, decreased potency. On palpation of the prostate gland, its increase, tenderness, and smoothness of the interlobar groove were noted. Leukocytes up to 30-40 in the field of vision were detected in the secretion of the prostate gland. The diagnosis of prostatitis was confirmed by ultrasound.

 Previously, all patients without sufficient effect were treated with antibiotics, biostimulants, pyrogenal. Moreover, several patients underwent repeated repeated courses of such treatment.

 Table 1 presents the dynamics of clinical and laboratory parameters after treatment with the proposed method, including endourethral electrophoresis of collalysine in patients with chronic prostatitis. As a comparison group, the results of treatment of 10 patients who underwent conventional therapy were summarized. Analysis of clinical and laboratory data shows that the disappearance of subjective and objective data occurs 5-6 days earlier than when using traditional therapies. Moreover, a positive clinical effect was noted in all patients. There were no side effects.

 Prior to the start of collarizine electrophoresis, all patients in the peripheral blood showed significant shifts towards hypocoagulation (an increase in the coagulation time of unstabilized blood was observed). After the course of treatment, a clear tendency to normalization in the hemostatic system was observed in all patients, which was characterized by a reduction in the coagulation time of unstabilized blood (see table 2).

 Example 1. Patient I., 23 years old. More than 6 months. Complaints of lumbago in the perineum. Diagnosis: chronic parenchymal prostatitis. Appointed endourethral electrophoresis with collalysine (500 KE in 3 ml of a 0.5% solution of novocaine), daily, for a course of 10 procedures. A distinct clinical effect of this drug was noted. Already on the 4th day of therapy, the patient noted the disappearance of burning in the urethra during urination, lumbago in the perineum. Sexual function recovered on day 7. From the side of peripheral blood: coagulation time of unstabilized blood before treatment is 7 minutes, after - 6.3 minutes. The prostate secretion returned to normal on day 6.

 Example 2. Patient A., 25 years old. Complaints of lower back pain. Sick for 2 years. Diagnosis: chronic parenchymal prostatitis. Appointed endourethral electrophoresis of collalysine (500 KE of collalysine in 3 ml of a 0.5% solution of novocaine), daily. There are 15 procedures per course. On the 3rd day of treatment, back pain disappeared. The prostate secretion returned to normal on day 5, sexual function recovered on day 8, soreness of the prostate disappeared on day 12, and the size of the prostate returned to day 12 of therapy. From the side of peripheral blood: coagulation time of unstabilized blood before treatment is 9 minutes, after - 5.3 minutes.

 Thus, the use of collalysine in the treatment of patients with chronic prostatitis significantly reduces the duration of treatment. Side effects are absent.

Sources of information
1. Burylina S.M., Pirogova V.A. Clinical and experimental study of collalizine activity in cicatricial skin formations // In: Pathogenesis, treatment and prevention of cosmetic diseases and deficiencies. M., 1982, - p. 156 - 160.

 2. Zavyalov A. I. Collalizin in the treatment of patients with limited scleroderma // Kazan honey. Journal. 1986, N 5, - p. 379.

 3. Ilyin I.I. Non-neococcal urethritis in men // M .: Medgiz, 1991, 286 p.

 4. Klyuev M.A. (ed.) Medicines used in medical practice // M .: Medicine, 1990. - 512 p.

Claims (1)

 The use of collalysine as a means of normalizing the hemostatic system by reducing the time of blood coagulation for the treatment of chronic prostatitis.

Images